Brian O Mahony/ X
Jul 12, 2026, 07:58
Brian O Mahony: Could NXT-007 Minimize the Need for Perioperative FVIII
Brian O Mahony, CEO of Irish Haemophilia Society, shared a post on X:
“Nogami ISTH 2026 NXT-007.
4 doses used in clinical trial.
FVIII equivalent varied from 13.8 percent to 93.1 percent.
Not sure any additional FVIII required-even for major surgery.”
Other posts featuring Brian O Mahony on Hemostasis Today.
-
Jul 12, 2026, 07:50Shayan Mohammadmoradi: Connecting the Next Generation of Hemostasis Researchers at ISTH 2026
-
Jul 12, 2026, 07:42Alexandra Yakusheva: ThrombInnov Debuts at ISTH 2026 with a Focus on Translational Research
-
Jul 12, 2026, 07:34Wolfgang Miesbach: ISTH 2026 Explores the Next Generation of APS Diagnostics
-
Jul 12, 2026, 07:28Sara Zalghout: ISTH 2026 Highlights Progress in Thromboinflammation Research
-
Jul 12, 2026, 07:13Ekaterina Balaian: Finding Healing Through Art at ISTH 2026
-
Jul 12, 2026, 06:59Maaike Sybil Jongen: Flow Cytometry for Platelet Phenotyping at ISTH 2026
-
Jul 12, 2026, 06:45Brian O Mahony: Advancing Concizumab Therapy for Hemophilia With Inhibitors at ISTH 2026
-
Jul 12, 2026, 06:42PERT-Guided Patient Selection for Advanced Pulmonary Embolism Therapies
-
Jul 12, 2026, 06:12Precision in Antithrombotic Therapy at ISTH 2026 – The Lancet Haematology